Latest news
Covid-19 nasal vaccine ready for clinical studies
Last week, Iconovo’s partner ISR received the reviewed and approved toxicology report that examined the company's vaccine for intranasal…
ICOpre trademarked in Japan
As part of Iconovos global commercialization plan, we are now strengthening our international IP portfolio by trademarking ICOpre in Japan.…
Press releases
Nov 01, 2021, 09:00
News
IR
English
Corporate Information
Other Corporate Information
Oct 29, 2021, 08:11
News
IR
English
Corporate Information
Other Corporate Information
Oct 28, 2021, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Sep 22, 2021, 15:15
News
IR
Swedish
Corporate Information
Other Corporate Information
Sep 20, 2021, 09:00
News
IR
English
Corporate Information
Other Corporate Information
Sep 20, 2021, 09:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Sep 15, 2021, 09:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 26, 2021, 14:09
News
IR
English
Corporate Information
Other Corporate Information
Aug 26, 2021, 14:09
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 25, 2021, 08:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 23, 2021, 11:04
News
IR
English
Corporate Information
Other Corporate Information
Aug 20, 2021, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q2
Jul 12, 2021, 09:00
News
IR
English
Regulatory
MAR
Corporate Information
Sales
Order
Jul 12, 2021, 09:00
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Jul 05, 2021, 14:59
News
IR
Swedish
Corporate Information
Other Corporate Information
Jul 01, 2021, 22:06
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
Jul 01, 2021, 22:06
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
Jul 01, 2021, 17:31
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
Jul 01, 2021, 17:31
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
May 26, 2021, 08:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se